Key Points
-
Pain processing involves neurons, microglia and astrocytes. The functions of glia extend beyond basic support for neurons. Once activated, they release various classic immune factors that are also neuroactive substances.
-
Glia express receptors for neurotransmitters and neuromodulators, so they can respond to neural activity.
-
Despite the integral part that glia play in neuronal communication, most of the drugs that are available for treating pathological pain in humans target neuronal mechanisms. This may be one reason for their limited therapeutic efficacy in pain control. Early evidence from preclinical studies with animal models of neuropathic pain suggest that shifting glial activation from a pro-inflammatory to an anti-inflammatory state may prove to be important in clinical pain phenomena.
-
Activated glia exert crucial neuroprotective and anti-inflammatory effects. Identifying ways to regulate the switch between the proinflammatory and the anti-inflammatory state of glial activation, rather than simply blocking glial actions, could be key to the development of more powerful strategies to treat clinical pain.
Abstract
Glia have emerged as key contributors to pathological and chronic pain mechanisms. On activation, both astrocytes and microglia respond to and release a number of signalling molecules, which have protective and/or pathological functions. Here we review the current understanding of the contribution of glia to pathological pain and neuroprotection, and how the protective, anti-inflammatory actions of glia are being harnessed to develop new drug targets for neuropathic pain control. Given the prevalence of chronic pain and the partial efficacy of current drugs, which exclusively target neuronal mechanisms, new strategies to manipulate neuron–glia interactions in pain processing hold considerable promise.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Campbell, J. N. & Meyer, R. A. Mechanisms of neuropathic pain. Neuron 52, 77–92 (2006).
Carr, D. B. & Goudas, L. C. Acute pain. Lancet 353, 2051–2058 (1999).
Long, D. M. et al. Persistent back pain and sciatica in the United States: patient characteristics. J. Spinal Disord. 9, 40–58 (1996).
Woolf, C. J. & Ma, Q. Nociceptors—noxious stimulus detectors. Neuron 55, 353–364 (2007).
Hunt, S. P. & Mantyh, P. W. The molecular dynamics of pain control. Nature Rev. Neurosci. 2, 83–91 (2001).
Spike, R. C. et al. MOR-1-immunoreactive neurons in the dorsal horn of the rat spinal cord: evidence for nonsynaptic innervation by substance P-containing primary afferents and for selective activation by noxious thermal stimuli. Eur. J. Neurosci. 15, 1306–1316 (2002).
Hucho, T. & Levine, J. D. Signaling pathways in sensitization: toward a nociceptor cell biology. Neuron 55, 365–376 (2007).
Miraucourt, L. S., Dallel, R. & Voisin, D. L. Glycine inhibitory dysfunction turns touch into pain through PKCgamma interneurons. PLoS ONE 2, e1116 (2007).
Tracey, I. & Mantyh, P. W. The cerebral signature for pain perception and its modulation. Neuron 55, 377–391 (2007).
Loeser, J. D. in Pain (eds Cervero, F. & Jensen, T. S.) 11–20 (Elsevier, Amsterdam, 2006).
Woolf, C. J. & Mannion, R. J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353, 1959–1964 (1999).
Woolf, G. & Salter, M. W. Neuronal plasticity: increasing the gain in pain. Science 288, 1765–1769 (2000).
Navarro, X., Vivo, M. & Valero-Cabre, A. Neural plasticity after peripheral nerve injury and regeneration. Prog. Neurobiol. 82, 163–201 (2007).
Zimmermann, M. Pathobiology of neuropathic pain. Eur. J. Pharmacol. 429, 23–37 (2001).
McMahon, S. B., Cafferty, W. B. J. & Marchand, F. Immune and glial cell factors as pain mediators and modulators. Exp. Neurol. 192, 444–462 (2005).
Scholz, J. & Woolf, C. J. The neuropathic pain triad: neurons, immune cells, and glia. Nature Neurosci. 10, 1361–1368 (2007). This review describes the development of neuropathic pain as a neuroimmune disorder that involves neuronal pathways as well as glia in the dorsal root ganglia and spinal cord.
Watkins, L. R., Wieseler-Frank, J., Milligan, E. D., Johnston, I. & Maier, S. F. in Handbook of Clinical Neurology (eds Cervero, F. & Jensen, T. S.) 309–323 (Elsevier, 2006).
Halassa, M. M., Fellin, T. & Hatdon, P. G. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol. Med. 13, 54–63 (2007).
Pocock, J. M. & Kettenmann, H. Neurotransmitter receptors on microglia. Trends Neurosci. 30, 527–535 (2007).
Haydon, P. G. Glia: listening and talking to the synapse. Nature Rev. Neurosci. 2, 185–193 (2001).
Kreutzberg, G. W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19, 312–318 (1996).
Nguyen, M. D., Julien, J. P. & Rivest, S. Innate immunity: the missing link in neuroprotection and neurodegeneration. Nature Rev. Neurosci. 3, 216–227 (2002).
Emery, B., Butzkueven, H., Snell, C., Binder, M. & Kilpatrick, T. J. Oligodendrocytes exhibit selective expression of suppressor of cytokine signaling genes and signal transducer and activator of transcription 1 independent inhibition of interferon-gamma-induced toxicity in response to leukemia inhibitory factor. Neuroscience 137, 463–472 (2006).
Slaets, H. et al. Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 8, 1237–1247 (2008).
Porter, J. T. & McCarthy, K. D. Astrocytic neurotransmitter receptors in situ and in vivo. Prog. Neurobiol. 51, 439–455 (1997).
Benveniste, E. N. in Immune and Glial Regulation of Pain (eds DeLeo, J. A., Sorkin, L. S. & Watkins, L. R.) 43–63 (IASP, Seattle, 2007).
Fellin, T. et al. in Novartis Foundation Symposium 208–217 (Wiley, Chichester, New York, 2006).
Parpura, V. et al. Glutamate-mediated astrocyte-neuron signalling. Nature 369, 744–747 (1994).
Zhuang, Z. Y., Gerner, P., Woolf, C. J. & Ji, R. R. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 114, 149–159 (2005).
Tawfik, V. L. et al. Induction of astrocyte differentiation by propentofylline increases glutamate transporter expression in vitro: heterogeneity of the quiescent phenotype. Glia 54, 193–203 (2006).
Sung, B., Lim, G. & Mao, J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J. Neurosci. 23, 2899–2910 (2003).
Ji, R. R. & Suter, M. R. p38 MAPK, microglial signaling, and neuropathic pain. Mol. Pain 3, 33 (2007).
Hickey, W. F. & Kimura, H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239, 290–292 (1988).
Lassmann, H., Schmied, M., Vass, K. & Hickey, W. F. Bone marrow derived elements and resident microglia in brain inflammation. Glia 7, 19–24 (1993).
Zhang, J. et al. Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J. Neurosci. 27, 12396–12406 (2007).
Romero-Sandoval, E. A., Horvath, R. J. & Deleo, J. A. Neuroimmune interactions and pain: focus on glial-modulating targets. Curr. Opin. Investig. Drugs 9, 726–734 (2008).
Griffiths, M., Neal, J. W. & Gasque, P. Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. Int. Rev. Neurobiol. 82, 29–55 (2007).
Medzhitov, R. & Janeway, C. A. Jr. Decoding the patterns of self and nonself by the innate immune system. Science 296, 298–300 (2002).
Olson, J. K. & Miller, S. D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 173, 3916–3924 (2004).
Carpentier, P. A., Duncan, D. S. & Miller, S. D. Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav. Immun. 22, 140–147 (2008).
Abdallah, B. et al. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum. Gene Ther. 7, 1947–1954 (1996).
Medzhitov, R. & Janeway, C. A. Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91, 295–298 (1997).
Beutler, B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257–263 (2004).
Allan, S. M., Tyrell, P. J. & Rothwell, N. J. Interleukin-1 and neuronal injury. Nature Rev. Immunol. 5, 629–640 (2005).
Aronica, E., Gorter, J. A., Rozemuller, A. J., Yankaya, B. & Troost, D. Activation of metabotropic glutamate receptor 3 enhances interleukin (IL)-1β-stimulated release of IL-6 in cultured human astrocytes. Neuroscience 130, 927–933 (2005).
Hanisch, U.-K. Microglia as a source and target of cytokines. Glia 40, 140–155 (2002).
Husemann, J., Loike, J. D., Anankov, R., Febbraio, M. & Silverstein, S. C. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia 40, 195–205 (2002).
Murphy, S. (ed.) Astrocytes: Pharmacology and Function (Academic, San Diego, 1993).
Faulkner, J. R. et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 24, 2143–2155 (2004).
Kim, D. et al. A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J. Biol. Chem. 282, 14975–14983 (2007).
Obata, K. et al. Toll-like receptor 3 contributes to spinal glial activation and tactile allodynia after nerve injury. J. Neurochem. 9 Apr 2008 (doi:10.1111/j.1471-4159.2008.05353.x).
Obata, K. et al. Toll-like receptor 3 contributes to spinal glial activation and tactile allodynia after nerve injury. J. Neurochem. 105, 2249–2259 (2008).
Tanga, F. Y., Nutile-McMenemy, N. & DeLeo, J. A. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc. Natl Acad. Sci. USA 102, 5856–5861 (2005).
Nasu-Tada, K., Koizumi, S., Tsuda, M., Kunifusa, E. & Inoue, K. Possible involvement of increase in spinal fibronectin following peripheral nerve injury in upregulation of microglial P2X4, a key molecule for mechanical allodynia. Glia 53, 769–775 (2006).
Hutchinson, M. R. et al. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence and reward. Sci. World J. 7, 98–111 (2007).
Hutchinson, M. R. et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur. J. Neurosci. 28, 20–29 (2008). The first demonstration that TLRs bind opioids. These data support an entirely new approach to controlling pain.
Johnston, I. N. et al. A role for pro-inflammatory cytokines and fractalkine in analgesia, tolerance and subsequent pain facilitation induced by chronic intrathecal morphine. 24, 7353–7365 (2004).
Hutchinson, M. R. et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav. Immun. 1 Jul 2008 (doi:10.1016/j.bbi.2008.05.004).
Hutchinson, M. R. et al. Minocycline supresses morphine-induced respiratory depression, supresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav. Immun. 31 Jul 2008 (doi:10.1016/j.bbi.2008.07.008).
Costigan, M. et al. Heat shock protein 27: developmental regulation and expression after peripheral nerve injury. J. Neurosci. 18, 5891–5900 (1998).
Ghosh, T. K. et al. Toll-like receptor (TLR) 2–9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell. Immunol. 243, 48–57 (2006).
Lissitsyn, Y., Becker, A. B., Kozyrskyj, A. L. & HayGlass, K. T. Level of Toll-like receptor agonist exposure differentially determines chemokine production in humans. Can. J. Physiol. Pharmacol. 85, 739–746 (2007).
van Noort, J. M. Stress proteins in CNS inflammation. J. Pathol. 214, 267–275 (2008).
Roelofs, M. F. et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J. Immunol. 176, 7021–7027 (2006).
Tsuda, M., Inoue, K. & Salter, M. W. Neuropathic pain and spinal microglia: a big problem from molecules in 'small' glia. Trends Neurosci. 28, 101–107 (2005). This review describes the role of microglia in the development of neuropathic pain.
Marchand, F., Perretti, M. & McMahon, S. B. Role of the immune system in chronic pain. Nature Rev. Neurosci. 6, 521–530 (2005).
Watkins, L. R., Milligan, E. D. & Maier, S. F. Spinal cord glia: new players in pain. Pain 93, 201–205 (2001).
Coull, J. A. et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438, 923–925 (2005). The first report to demonstrate a mechanism for enhanced pain signalling that is mediated by microglia.
Svensson, C. I. et al. Spinal p38β isoform mediates tissue injury-induced hyperalgesia and spinal sensitization. J. Neurochem. 92, 1508–1520 (2005).
Kawasaki, Y. et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nature Med. 14, 331–336 (2008).
Asensio, V. C. & Campbell, I. L. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci. 22, 504–512 (1999).
Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217–242 (2000).
Tran, P. B. & Miller, R. J. Chemokine receptors: signposts to brain development and disease. Nature Rev. Neurosci. 4, 444–455 (2003).
White, F. A. et al. Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc. Natl Acad. Sci. USA 102, 14092–14097 (2005).
Zhang, J. & De Koninck, Y. Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J. Neurochem. 97, 772–783 (2006). This study demonstrated that peripheral immune–CNS interactions lead to neuropathic pain through chemokine action.
Dansereau, M. A. et al. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J. Neurochem. 106, 757–769 (2008).
Jung, H., Toth, P. T., White, F. A. & Miller, R. J. Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J. Neurochem. 104, 254–263 (2008).
Thacker, M. A. et al. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur. J. Pain 11 Jun 2008 (doi:10.1016/j.ejpain.2008.04.017).
Clark, A. K. et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc. Natl Acad. Sci. USA 104, 10655–10660 (2007).
Lindia, J. A., McGowan, E., Jochnowitz, N. & Abbadia, C. Induction of CX3CL1 expression in astocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J. Pain 6, 434–438 (2005).
Milligan, E. D. et al. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur. J. Neurosci. 20, 2294–2302 (2004).
Milligan, E. D. et al. An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur. J. Neurosci. 22, 2775–2782 (2005).
Zhuang, Z.-Y. et al. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav. Immun. 21, 642–651 (2007).
White, F. A., Jung, H. & Miller, R. J. Chemokines and the pathophysiology of neuropathic pain. Proc. Natl Acad. Sci. USA 104, 20151–20158 (2007). A comprehensive review that describes the role of chemokines in pain signalling.
Verge, G. M. et al. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur. J. Neurosci. 20, 1150–1160 (2004).
Beattie, E. C. et al. Control of synaptic strength by glial TNFα. Science 295, 2282–2285 (2002).
Stellwagen, D. & Malenka, R. C. Synaptic scaling mediated by glial TNF-α. Nature 440, 1054–1059 (2006).
Petrenko, A. B., Yamakura, T., Baba, H. & Shimoji, K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth. Analg. 97, 1108–1116 (2003).
Viviani, B. et al. Interleukin-1β enhances NMDA receptor-mediated intracellular calcium release through activation of the Src family of kinases. J. Neurosci. 23, 8692–8700 (2003).
Zhang, R. X. et al. IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. Pain 135, 232–239 (2008).
Kawasaki, Y., Zhang, L., Cheng, J.-K. & Ji, R.-R. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1β, interleukin-6, and tumor necrosis factor-α in regulating synaptic and neuronal activity in the superficial spinal cord. J. Neurosci. 28, 5189–5194 (2008).
Ozaktay, A. C. et al. Effects of interleukin-1 beta, interleukin-6, and tumor necrosis factor on sensitivity of dorsal root ganglion and peripheral receptive fields in rats. Eur. Spine J. 15, 58–66 (2006).
Besson, J. M. The neurobiology of pain. Lancet 353, 1610–1615 (1999).
Glezer, A., Simard, R. S. & Rivest, S. Neuroprotective role of the innate immune system by microglia. Neuroscience 147, 867–883 (2007). This review considers the beneficial role of activated microglia in the CNS.
Elward, K. & Gasque, P. “Eat me” and “don't eat me” signals govern the innate immune response and tissue repair in the CNS: emphasis on the critical role of the complement system. Mol. Immunol. 40, 85–94 (2003).
Tassiulas, I. et al. Apoptotic cells inhibit LPS-induced cytokine and chemokine production and IFN responses in macrophages. Hum. Immunol. 68, 156–164 (2007).
Turrin, N. P. & Rivest, S. Molecular and cellular immune mediators of neuroprotection. Mol. Neurobiol. 34, 221–242 (2006).
Tibrewal, N. et al. Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-κB transcriptional activation. J. Biol. Chem. 283, 3618–3627 (2008).
DeLeo, J. A., Sorkin, L. S. & Watkins, L. R. (eds) Immune and Glial Regulation of Pain (IASP, Seattle, 2007). A book dedicated to understanding the current evidence and ideas regarding the roles that glia play in pain processing.
Blais, V. & Rivest, S. Effects of TNF-α and IFN-γ on nitric oxide-induced neurotoxicity in the mouse brain. J. Immunol. 172, 7043–7052 (2004).
Suzuki, T. et al. Production and release of neuroprotective tumor necrosis factor by P2X7 receptor activated microglia. J. Neurosci. 24, 1–7 (2004).
Inoue, K. The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol. Therapeut. 109, 210–226 (2006). A comprehensive review that addresses the role of purinoceptors on microglia in neuropathic pain.
Kaushal, V. & Schlichter, L. C. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J. Neurosci. 28, 2221–2230 (2008).
Hacker, H. et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439, 204–207 (2006).
Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O'Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683–765 (2001).
Milligan, E. M. et al. in Immune and Glial Regulation of Pain (eds De Leo, J. A., Sorkin, L. S. & Watkins, L. R.) 319–337 (IASP, Seattle, 2007).
Flatters, S. J., Fox, A. J. & Dickenson, A. H. Nerve injury alters the effects of interleukin-6 on nociceptive transmission in peripheral afferents. Eur. J. Pharmacol. 484, 183–191 (2004).
Watkins, L. R. & Maier, S. F. Glia: a novel drug discovery target for clinical pain. Nature Rev. Drug Discov. 2, 973–985 (2003).
Mika, J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol. Rep. 60, 297–307 (2008).
Tawfik, V. L., Nutile-McMenemy, N., Lacroix-Fralish, M. L. & Deleo, J. A. Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav. Immun. 21, 238–246 (2007).
Watkins, L. R. & Maier, S. F. Targeting glia to control clinical pain: an idea whose time has come. Drug Discov. Today Ther. Strat. 1, 83–88 (2004).
Goss, J. R., Goins, W. F. & Glorioso, J. C. Gene therapy applications for the treatment of neuropathic pain. Expert Rev. Neurother. 7, 487–506 (2007). A comprehensive, up-to-date review describing the application of gene therapy to the CNS for chronic pain control.
Schwartz, M., Butovsky, O., Bruck, W. & Hanisch, U. K. Microglial phenotype: is the commitment reversible? Trends Neurosci. 29, 68–74 (2006). Reviews the many factors that act in the CNS to alter the way in which microglia are activated, with an emphasis on the varying chemical signals that significantly influence microglial phenotype.
Butovsky, O. Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7–2 (CD86) and prevention of cyst formation. FASEB J. 15, 1065–1067 (2001).
Manzanares, J., Julian, M. & Carrascosa, A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr. Neuropharmacol. 4, 239–257 (2006).
Ashton, J. C. & Glass, M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol. 5, 73–80 (2007). This article reviews the in vitro and in vivo evidence that glia are regulated by cannabinoids in neuroprotection and neurodegeneration, with a particular focus on the cannabinoid CB2 receptor, which has emerged as a potential target for the treatment of neuropathic pain.
Beltramo, M. et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 23, 1530–1538 (2006).
Gebhart, G. F. Descending modulation of pain. Neurosci. Biobehav. Rev. 27, 729–737 (2004).
Millan, M. J. Descending control of pain. Prog. Neurobiol. 66, 355–474 (2002).
Ji, R. R. & Woolf, C. J. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol. Dis. 8, 1–10 (2001). A clear and thorough review that describes intracellular signalling and the role that microglia have in the development of neuropathic pain.
Hains, B. C. & Waxman, S. G. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J. Neurosci. 26, 4308–4317 (2006).
Ma, J. Y. & Zhao, Z. Q. The involvement of glia in long-term plasticity in the spinal dorsal horn of the rat. Neuroreport 13, 1781–1784 (2002).
Ledeboer, A. et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115, 71–83 (2005).
Tanga, F. Y., Raghavendra, V. & De Leo, J. A. Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic markers in a rat model of neuropathic pain. Neurochem. Int. 45, 397–407 (2004).
Wieseler-Frank, J. et al. A novel immune-to-CNS communication pathway: cells of the meninges surrounding the spinal cord CSF space produce proinflammatory cytokines in response to an inflammatory stimulus. Brain Behav. Immun. 21, 711–718 (2007).
Meller, S. T., Dykstra, C., Grzybycki, D., Murphy, S. & Gebhart, G. F. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 33, 1471–1478 (1994).
Raghavendra, V., Tanga, F. Y. & DeLeo, J. A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306, 624–630 (2003).
Federici, T. & Boulis, N. M. Ribonucleic acid interference for neurological disorders: candidate diseases, potential targets and current approaches. Neurosurgery 60, 3–16 (2007).
Ledeboer, A. M. et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav. Immun. 21, 686–698 (2007).
Milligan, E. D. et al. Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. Neuron Glia Biol. 2, 293–308 (2006).
Kaplitt, M. G. & During, M. J. Gene Therapy in the Central Nervous System: From Bench to Bedside (Elsevier, San Diego, USA, 2006).
Mata, M., Hao, S. & Fink, D. J. Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNFα. Neurosci. Lett. 437, 209–213 (2008).
Storek, B. et al. Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc. Natl Acad. Sci. USA 105, 1055–1060 (2007).
Cabral, G. A., Raborn, E. S., Griffin, L., Dennis, J. & Marciano-Cabral, F. CB2 receptors in the brain: role in central immune function. Br. J. Pharmacol. 153, 240–251 (2008).
Eljaschewitsch, E. et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49, 67–79 (2006).
Acknowledgements
This work was supported by NIH grants: DA018156, DA015642 and DA015656.
Author information
Authors and Affiliations
Corresponding author
Glossary
- Acute pain
-
A sensation that results from a transient, high-intensity stimulation that exceeds a threshold for the activation of specialized nerve endings located on nociceptive sensory fibres; it often leads to tissue damage.
- Pathological pain
-
Pain that is associated with inflammation and/or trauma of peripheral tissue or nerves after injury.
- Neuropathic pain
-
Pathological pain that is often persistent and is produced by damage to peripheral nerves or by lesions of the CNS.
- Cytokine
-
A chemical signal released by immune cells that significantly alters many cell types, including other immune cells.
- Chemokine
-
A class of cytokine that was originally identified as having chemotactic properties. To date, ∼50 chemokines have been identified. Chemokines are classified according to the number and spacing of conserved cysteine residues in their amino termini.
- Nociceptive neuron
-
A sensory neuron that specifically responds to noxious stimuli and contains a bifurcating axon, with one branch projecting to the periphery and the other to the CNS.
- Dorsal root ganglia
-
(DRG). Clusters of primary sensory neurons of the peripheral somatosensory system. These ganglia are adjacent to the spinal cord and send axons to the dorsal horn of the spinal cord.
- Spinal cord laminae
-
Laminae (also known as layers) of the spinal cord that are organized by the type of information that they receive from the body. Laminae I and II, located in the superficial portion of the dorsal spinal cord, receive information from peripheral afferent nociceptive fibres. Laminae III–VI receive information about non-noxious stimuli and proprioceptive information. Lamina V plays an important part in the transmission of noxious information to supra-spinal pain centres.
- Chronic pain
-
Persistent pain with an indefinite duration. It can originate from tissue and/or nerve damage and becomes chronic pain when it is prolonged and no longer has a clearly defined underlying cause.
- Blood–brain barrier
-
A unique, selective barrier that makes blood vessels in the CNS highly impermeable to substances carried in the blood stream. Drugs must be able to cross the blood–brain barrier in order to achieve therapeutic levels in the CNS.
- Toll-like receptors
-
(TLRs). Pattern-recognition receptors expressed on cells of the innate immune system that recognize microbial particles, leading to clearance, cell death and inflammation.
- Meninges
-
Three membranous layers (the dura mater, arachnoid mater and pia mater) that surround the spinal cord and cerebrospinal fluid space.
Rights and permissions
About this article
Cite this article
Milligan, E., Watkins, L. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 10, 23–36 (2009). https://doi.org/10.1038/nrn2533
Issue Date:
DOI: https://doi.org/10.1038/nrn2533